NSN 6505-01-693-8769 · NIIN 016938769 · FSC 6505
NO DASHES 6505016938769
In Stock
INMAZEB INJECTION
Drugs and Biologicals
Technical characteristics
2 rows
Straight from the federal item record. Entries the record leaves empty are shown empty — nothing is filled in on its behalf.
| MRC | Requirement | Value |
|---|---|---|
| FEAT | SPECIAL FEATURES | ATOLTIVIMAB, MAFTIVIMAB,AND ODESIVIMAB EBGN) INJECTION 241.7 MG / 241.7 MG / 241.7 MG PER 14.5 ML. SINGLE DOSE VIAL. INDICATED FOR THE TREATMENT OF INFECTION CAUSED BY ZAIRE EBOLAVIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES; TREATMENT IS MOST EFFECTIVE WHEN GIVEN EARLY IN THE COURSE OF THE DISEASE; INMAZEB (ATOLTIVIMAB, MAFTIVIMAB & ODESIVIMAB-EBGN) IS A NOVEL ANTIBODY MEDICINE; INMAZEB IS ADMINISTERED AS A SINGLE, WEIGHT BASED INTRAVENOUS INFUSION; REFRIGERATE AT 2 TO 8 DEGREES CELSIUS( 36F TO 46F) IN THE ORIGINAL CARTON TO PROTECT FROM LIGHT; DO NOT FREEZE OR SHAKE; DOES NOT CONTAIN PRESERVATIVES; SINGLE DOSE VIAL. |
| CXCY | PART NAME ASSIGNED BY CONTROLLING AGENCY | INMAZEB INJECTION SOLUTION, VIAL |